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Bladder cancer has the highest recurrence rate of any cancer. The American Urological Association recommends cystoscopic
surveillance every 3–6 months for 3 years, and at least once a year thereafter, particularly for high-risk patients; however, cystoscopy is invasive, expensive, and is not without insignificant morbidity for the patient. Urine cytology is often used as an
adjunct to cystoscopy; however, it has a low sensitivity in detecting low grade bladder cancers. Recent studies have investigated
the application of Raman micro-spectroscopy for the detection of bladder cancer via urine cytology, and it has been demonstrated
to significantly improve the diagnostic sensitivity of urine cytology for low grade bladder cancer under ideal experimental conditions. In this paper we attempt to move Raman micro-spectroscopy a step closer to the clinic by systematically examining the
potential of this technology to classify low and high grade bladder cancer cell lines under the stringent clinical conditions that
can be expected in the standard pathology laboratory, in terms of consumables, protocols, and instrumentation. We show that
the use of glass slides, traditional fixing agents, lengthy exposure to urine, red blood cell lysing agents, as well as common cell
deposition methods, do not significantly impact on the diagnostic potential of Raman based urine cytology. This study suggests
that urine samples prepared with the ThinPrep R UroCyteTM method and analysed with micro-Raman spectroscopy could provide
a useful alternative to cystoscopy for long term bladder cancer surveillance.

1

Introduction

Bladder cancer, otherwise known as urothelial carcinoma (UC), is the seventh most common cancer in the UK,
with around 10,000 people being diagnosed every year, the
majority of which are diagnosed in males. UC has the highest recurrence rate of any cancer, and it has been reported as
the most expensive malignancy from diagnosis to death for
health care systems, costing the NHS in the UK approximately
£55 million a year. 1–3 Urine cytology coupled with cystoscopic examination is the standard for bladder cancer diagnostics. However, cystoscopy is invasive, expensive and may miss
some flat lesions. Approximately 75% of patients present with
superficial disease (Ta or T1), known as non-muscle invasive
bladder cancer (NMIBC), and the majority of new diagnoses
do not require a radical cystectomy with urinary diversion.
These patients are managed with an endoscopic procedure via
the urethra, to ‘scrape’ the tumour from the lining of the blada
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der, ensuring that the deep margins of the tumour are completely resected, and the surrounding abnormal or dysplastic
mucosa is adequately fulgrated. This procedure is known as
a trans-urethral resection of the bladder tumour (TURBT). In
many cases of NMIBC, lifelong cystoscopic surveillance is
recommended due to the high rate of recurrence, which results
in significant costs for the patient and the health care system.
A particularly aggressive variant of NMIBC is termed carcinoma in situ (CIS). Without any treatment, approximately
54% of patients with CIS progress to muscle-invasive disease. 4 One of the more challenging aspects of diagnosing
bladder cancer is detecting CIS, which is often invisible or
present as a non-specific area of inflammation in the bladder.
Voided urine cytology is a useful non-invasive adjunct in
the diagnosis of UC. Examination of voided urine for exfoliated cells has high sensitivity in high grade tumours, but low
sensitivity in low grade tumours. 5 Diagnostic delays lead to
delayed management of the cancer with resultant poorer outcomes for the patient. Therefore, early detection of urothelial
lesions is important in order to optimise patient treatment, reduce costs, and to improve patient anxiety.
Of particular concern for public health systems internationally is the approach to surveillance for patients previously diagnosed and treated for NMIBC. This particular subset of UC
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has a high rate of recurrence, and therefore, these patients remain on costly invasive cystoscopic surveillance programmes
for the remainder of their lives. Previous research has been
carried out into the usefulness of urinary cytology versus cystoscopy in the follow-up of NMIBC. 6,7 To reduce the number of cystoscopy procedures for both healthcare systems and
patients, urinary markers could be used to detect recurrent tumours before they become large and numerous. However, urinary cytology is limited by its low sensitivity for low grade
tumours, and whilst urinary biomarkers are better at detecting
these tumours, they are still unable to detect half of the low
grade tumours that have been identified by cystoscopy. 6,8 According to current knowledge, no urinary marker can replace
cystoscopy during follow-up, or help to lower cystoscopic frequency in a routine fashion. 9
1.1

Standard urine cytology

Urinary cytology is usually requested for patients with unexplained hematuria, irritative voiding symptoms, patients suspected of bladder cancer, and patients monitored for bladder tumour recurrence. The predominant cellular component
of urine cytology is normal urothelial cells, which can vary
greatly in numbers, sizes, and shapes. These cells may appear as mononuclear cells that may be columnar, cuboidal, and
parabasal-like or polyhydral. Other normal cellular components found in urine cytology include urothelial clusters, papillary fragments, squamous and glandular cells, renal tubular
cells and casts, and prostatic and seminal vesicle cells. 10 Inflammation, infective pathogens, and blood components are
also found across many samples. Therefore, the process of
isolating, and identifying, urothelial tumour cells within a
voided urine sample can be challenging, particularly for low
grade urothelial carcinoma.
Cytologically, high grade urothelial carcinomas are relatively easy to diagnose with a high degree of sensitivity and
specificity due to the presence of anaplastic cells. These cells
have high nucleus to cytoplasm (N/C) ratios; the nuclei are
often eccentric with large irregular nucleoli. On the other
hand, low grade urothelial carcinomas have a low diagnostic sensitivity and specificity; these tumours are cytologically
characterised by increased cellularity, and the presence of an
increased number of urothelial clusters that may or may not
be papillary. The cells in these clusters have high N/C ratios
with nuclei bulging out of the cytoplasm. CIS is a flat lesion
and is the precursor to most invasive urothelial cancers. Cytology plays an important role in the detection of urothelial
CIS since these lesions may be multifocal and not visualised
on cystoscopy. These cells are large with high N/C ratios. 10
Other types of urothelial malignancies which may be present
include squamous carcinoma, adenocarcinoma, small cell carcinoma, lymphoma, or metastatic tumour cells from different
2|
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neoplastic primaries.
The specificity of cytology is greater than 90% and the sensitivity is ∼80% for high grade UC; however, the sensitivity
is 20–50% for low grade UC. 11 The main reason for this is
due to the fact that low grade tumour cells have a similar cytomorphology to normal urothelial cells, and the observation
of increased cellularity or papillary fragments which are associated with UC may instead be related to lithiasis, infection,
or urinary tract instrumentation. The cohesive nature of low
grade tumours may also result in less cells being shed into the
urine. 2
The examination of voided urine, or bladder-washing specimens, for exfoliated cancer cells has high sensitivity in high
grade tumours, but low sensitivity in low grade tumours. The
sensitivity in CIS detection varies among reports from 28–
100%. 12 Cytology is useful, particularly as an adjunct to cystoscopy, when a high grade malignancy or CIS is present.
Positive voided urinary cytology can indicate a urothelial tumour anywhere in the urinary tract; negative cytology, however, does not exclude the presence of a tumour. Cytological interpretation is highly user dependent. 13 Evaluation can
be hampered by low cellular yield, urinary tract infections,
stones, recent intravesical instrumentation, or instillations, but
in experienced hands specificity exceeds 90%. 14
The most valuable sample for urine cytology is typically
not the “first morning” specimen since the overnight exposure
to urine can result in the degeneration of many cells, therefore the “second morning” voided sample is often preferred.
Collection should be as a “clean catch”, “mid-stream” sample into a vial containing a preserving solution such as ethanol
or PreservCytTM (0234004, Hologic, Screenlink Healthcare,
UK) to prevent further cell degradation, following which the
sample should be stored in a fridge (4o C) until it can be processed. Catheterized urine should also be suitable for urine
cytology. 15
With respect to the current European Association of Urology guidelines, there are three specific recommendations relating to urine cytology: (1) cystoscopy is recommended
in all patients with symptoms suggestive of UC, it cannot
be replaced by cytology or by any other non-invasive test;
(2) voided urine cytology is advocated to predict high grade tumours before trans-urethral resection of the lesion; and (3) cytology should be performed on fresh urine with adequate fixation, morning urine is not suitable because of the frequent
presence of cytolysis. 16
1.2

Raman based urine cytology

Raman micro-spectroscopy is a powerful technique for the
identification and classification of cancer cells and tissues.
The prefix “micro” indicates that a Raman spectroscopy system is integrated into a microscope such that Raman spectra

may be obtained from sub-micron areas in a sample. Raman
spectroscopy is based on the inelastic scattering of light, and
occurs when incident laser photons interact with molecular
bonds in the sample, resulting in emitted photons of a different
energy. The magnitude of this shift in energy between photons
is dependent on the molecular structure of the sample being
analysed, it can either have a greater energy (anti-Stokes) or
lesser energy (Stokes) than the incident photon depending on
the vibrational and rotational energy states of the molecules in
the sample; here we are only concerned with the Stokes scattered photons. A typical Raman micro-spectroscopy set-up
is described in Section 3.2. Raman spectroscopy can identify biomolecular changes within cells as they progress from
a healthy to a cancerous state. In recent years, the applications of Raman spectroscopy to biological cells has increased,
with many reporting the application of Raman spectroscopy
to analyse and accurately classify cervical, bladder, and oral
cytological samples. 11,17–19
Multivariate statistical analysis is often applied to Raman
spectroscopic data for classification. This involves the application of statistical algorithms that are based on pattern
recognition techniques, such as Principal Components Analysis (PCA) or Linear Discriminant Analysis (LDA), in order
to identify subtle changes across datasets that can be used to
accurately differentiate between different pathological groups
and subgroups. 20 Lyng et al. recently applied Raman microspectroscopy with PC-LDA to accurately identify cervical
carcinoma from cervical smear samples obtained from over
60 patients. 17
Recent studies based on the application of Raman spectroscopy to urine cytology have shown good results for
analysing and classifying disease in bladder cells. In 2008,
Harvey et al. 21 used Raman optical tweezers to trap and analyze both live and chemically fixed bladder cell lines, and were
able to differentiate between normal and cancerous cells. In
2009, Harvey et al. continued to develop this application by
performing a comparison between SurePathTM (Becton Dickinson, US) and formalin fixing agents, as well as monitoring the effect of urine exposure times on bladder cell lines. 22
They discovered spectral contamination present in the spectra
recorded from SurePath fixed cells, which was not found in
the formalin group. The authors also compared unfixed cells
that were exposed to urine for a range of time points from
15 min to 12 h, and based on a PC-LDA model, it was reported that, in general, the prediction values did not deteriorate
over 12 h. In 2011, Canetta et al. 23 applied modulated Raman
micro-spectroscopy to bladder cell lines that were exposed to
urine and PreservCyt in a 2:1 ratio, centrifgued, fixed again
with PreservCyt, and resuspended in PBS. Based on PCA of
the modulated data, they were able to distinguish between two
cell lines with >80% sensitivity and specificity after 6 h exposure to urine.

Shaprio et al. 24 were the first group to apply Raman spectroscopy to fresh epithelial cells from human urine samples.
Voided urine samples were obtained from 340 patients (116
without UC, 92 with low grade UC, and 132 with high grade
UC), and Raman spectra were recorded from unfixed cells on
aluminium slides, and based only on the 1584 cm−1 Raman
peak, they reported classification between healthy and cancerous cells with >90% sensitivity and specificity.
The objective of this paper is to investigate if Raman microspectroscopy can successfully classify low and high grade
cell lines under the stringent conditions imposed by a typical
pathological laboratory. In order to achieve this, five experiments that systematically examine the performance of Raman
based urine cytology for cell classification across a range of
parameters are proposed. These experiments include an investigation of common fixing agents, urine exposure times of
up to 72 h, the use of inexpensive glass substrates, the addition of whole blood to simulate hematuria, as well as the use
of a standard red blood cell lysing agent, and finally the application of a commercial ThinPrep R 2000 Processor (T2) to
deposit cells from urine onto a glass slide. The breakdown of
this paper is as follows: Section 2 describes the motivation for
each of the individual experiments that were carried out; Section 3 outlines the methods used for each experiment, the results obtained from every experiment are shown in Section 4,
and this is finally followed by a conclusion and discussion in
Section 5.
In the first experiment a comparison is made between the
Raman spectra of low and high grade bladder cancer cells
lines that are fresh/unfixed, formalin fixed, and PreservCyt
fixed, and their associated classification accuracies. In the second experiment, a comparison between the spectra obtained
from cells on glass and Raman-grade calcium fluoride substrates is made in terms of cost and classification sensitivities and specificities. In the third experiment, bladder cancer cell lines are placed in a vial of urine and the commercially available methanol based preservative PreservCyt (2:1
ratio) for 5 h, 24 h and 72 h, and the impact of urine exposure
on cell spectra and their statistical classification is monitored
across these time frames. In the first three experiments, the
method of depositing the bladder cells on to the substrate was
a basic drop-dry method. In the fourth experiment, a different
cell deposition method is examined using the commercial T2
machine, where we employ the standard ThinPrep UroCyte
method used for urine cytology. In the fifth and final experiment, whole blood is added to these urine/cell solutions to
replicate samples that contain scant and frank hematuria respectively. This allows us to determine whether or not samples with hematuria can be processed using the commercial
red blood cell lysing agent CytoLytTM (0236004, Hologic,
Screenlink Healthcare, UK) and can then be investigated using Raman micro-spectroscopy for bladder cancer diagnostics.
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All ThinPrep prepared slides were also stained with haematoxylin and eosin (H&E) after Raman spectra were recorded
in order to determine if morphological analysis could be performed by a pathologist after Raman spectral acquisition has
taken place. It should be noted that typically a Papanicolaou (Pap) stain is used for fluid cytology in pathological laboratories, and it has been shown by Sahu et al. that this stain
can be applied after Raman spectral acquisition. 25

2
2.1

Motivation
Experiment 1: Fixing agents

A comparison between fresh, formalin fixed, and PreservCyt
fixed UC cells is the basis of our first experiment. This initial
study allows for the identification of biomolecular differences
that were introduced to the UC cell samples by these fixation methods, and provides information on the impact these
changes have on the capacity of multivariate statistical algorithms to classify between low and high grade UC cell lines.
In order to minimise the number of variables in this initial experiment, these cells were not exposed to urine.
2.2

Experiment 2: Substrates

Another important factor is the type of sample substrate that
is used in the study, and although it has been shown that better quality spectra can be recorded from expensive substrates
such as Raman-grade calcium fluoride, quartz or aluminium, a
number of issues arise on the use of these substrates in a pathological lab. Most importantly, the cost per substrate can be
prohibitively expensive (e.g. a single high purity calcium fluoride slide currently costs over £100), and when one considers
the high throughput of samples in a pathology lab, it becomes
clear that a hospital consumables budget will not cover the expense of these substrates. Whilst it is possible to clean and
re-use these substrates, many hospital guidelines recommend
the storage of human samples for a number of years, which
means that substrate re-use is not possible. Therefore, the use
of glass substrates is preferable as these are relatively inexpensive, and readily available within a pathology lab. However,
the background signal from glass poses a problem; this signal is particularly strong for NIR source wavelengths, and is
also appreciable for visible wavelengths. It has recently been
shown that when glass slides are used in conjunction with a
visible laser, such as a 532 nm laser, and a robust background
subtraction method, the resultant cell spectra can be comparable to those from more expensive substrates. 26
In contrast, Raman-grade calcium fluoride substrates produce a relatively flat background within the fingerprint region,
and are often preferred for more accurate analysis using Raman micro-spectroscopy, although at a much higher cost. 26
4|
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This experiment provides a comparison between Raman spectra recorded from UC cells on both glass and Raman-grade
calcium fluoride substrates, and enables us to gauge the impact of the background signal from glass on diagnostic classification.
2.3

Experiment 3: Urine exposure times

An important consideration is the length of time that cells can
remain within the urine solution before Raman based classification becomes unreliable. It has previously been shown that
it is possible to distinguish between different cell types after exposure to urine using Raman micro-spectroscopy. 22–24
However, it should be noted that these previous studies dealt
with cells that were exposed to urine for relatively short periods of time. In order to analyse urine samples from a clinic,
it is impractical to design a Raman study based around fresh,
unfixed samples; this is due to the rapid deterioration of cells
in urine, and the fact that recording all cells on a slide using
Raman spectroscopy is typically a time-consuming process.
To overcome this problem, standard urine cytology involves
the addition of a preserving agent into the urine collection vial
such as an ethanol or a methanol based solution; 2,23 however,
the impact of these agents on the recorded spectra, and the capability of multivariate statistical algorithms to classify different cell types after fixing, must be considered. Additionally,
in standard urine cytology the cells are fixed again after the
urine solution has been decanted. Typical agents used here are
formalin, SurePath or PreservCyt. 22,27–29
The third experiment deals with the impact of urine on cells
over 72 h in the presence of PreservCyt (2:1 ratio), followed
by an additional PreservCyt fixation step after the urine has
been decanted. Three time points are chosen for analysis: 6 h,
24 h, and 72 h, with 72 h representing the maximum expected
time frame for the transfer of a urine sample from the clinic to
the lab for analysis.
2.4

Experiment 4: ThinPrep UroCyte

Urine cytology is usually performed with a liquid based processing technique such as SurePath or ThinPrep. These systems are designed to prepare uniform monolayer cells onto
glass slides with minimal cell debris or blood residue in the
background. SurePath is a density gradient based cell enrichment process that fixes cells with an ethanol based solution,
whereas ThinPrep is a filter based cell concentration technique
that uses the methanol based solutions PreservCyt and CytoLyt. 30 ThinPrep UroCyte is the standard method used for
the preparation of urine samples with the T2 machine. This
process involves combining fresh urine with PreservCyt (2:1
ratio), followed by centrifugation and decantation of the supernatant. The cell pellet is resuspended in 30 ml CytoLyt to

lyse red blood cells present in the sample. This solution is
vortexed and centrifuged, the supernatant is poured off, and
finally the cell pellet is resuspended in 15 ml PreservCyt for
15 min, before being inserted into the T2 machine where the
cells are transferred onto a glass slide. Typically, for standard urine cytology, these slides are stained with Pap or H&E,
which facilitates visual evaluation by the pathologist.
In the fourth experiment in this study, the feasibility of
preparing urine/cell solutions with the ThinPrep UroCyte
method for Raman micro-spectroscopy is investigated. There
are two subgroups within this experiment: (1) application of
only PreservCyt, and (2) application of both PreservCyt and
CytoLyt; this enables a make direct comparisons of both methods, and the impact of CytoLyt on UC cells can be identified
in isolation.
2.5

Experiment 5: Hematuria

Hematuria is the most common symptom present in patients
diagnosed with bladder cancer, occurring in approximately
90% of cases. 31 Whilst hematuria may be intermittent for patients, it is important to consider the impact of red blood cells
in urine samples when analysing these samples using Raman
micro-spectroscopy. Red blood cells are known to produce a
large signal that can often swamp the weak Raman spectrum
obtained from epithelial cells. Urine solutions that contain
blood can be treated with red blood cell lysing agents such as
the combination of H2 O2 , ethanol, and industrial methylated
spirits as reported by Bonnier et al. 17 , or CytoLyt, which is
part of the standard ThinPrep cytology method currently used
in many pathology laboratories.
In this final experiment, the impact of both scant and frank
hematuria on Raman based classification of UC cell lines is
investigated. Samples are processed using the ThinPrep UroCyte method, in conjunction with CytoLyt in order to lyse any
red blood cells that may be present.

3
3.1

Methods

exceeding 15 min). An equal volume of 5% serum-containing
medium was added to the flask to neutralise the trypsin enzyme. The entire contents of the flask was transferred into a
sterilin container, and centrifuged at 1200 rpm for 5 min. The
supernatant was removed, and the cell pellet was resuspended
in fresh medium. This solution was centrigued at 1200 rpm
for 5 min, the medium was decanted, and the cells were resuspended in 1 ml PBS. This step was repeated and the cell pellets
were then processed as explained later in Sections 3.1.2–3.1.6.
3.1.2 Experiment 1: Fixing agents
In order to compare between fresh, formalin fixed, and PreservCyt fixed cells, the samples were prepared as follows:
(A) Fresh/unfixed: the cell pellet was suspended in 2 ml
PBS, followed by centrifugation at 1200 rpm for 5 min. The
PBS was decanted, and the cell pellet was resuspended in
1 ml PBS. A volume of 30 µl of this cell suspension was
dropped onto a glass substrate and left to air dry at room temperature for 2-3 hours.
(B) Formalin fixation: 10% neutral buffered formalin (HT501128, Sigma Aldrich, US) was passed through a
0.2 µm filter (Minisart filters, Sigma Aldrich, US) in order to
remove any large salt crystals present in the solution. The cell
pellet was suspended in 2 ml of formalin and left for 10 min at
room temperature. The solution was centrifuged at 1200 rpm
for 5 min, the supernatant was decanted, and the cells were resuspended in 2 ml PBS. The resulting solution was again centrigued at 1200 rpm for 5 min, the supernatant decanted, and
the cells were resuspended in 1 ml PBS. A volume of 30 µl
of this cell suspension was dropped onto a glass substrate and
left to air dry at room temperature for 2-3 hours.
(C) PreservCyt fixation: the cell pellet was suspended in
20 ml of PreservCyt and left for 15 min at room temperature.
The solution was centrifuged at 1200 rpm for 5 min, the supernatant was decanted and the cells were resuspended in 2 ml
PBS. This solution was centrigued at 1200 rpm for 5 min, the
supernatant was decanted and the cells were resuspended in
1 ml PBS. A volume of 30 µl of this cell suspension was
dropped on to a glass substrate, and left to air dry at room
temperature for 2-3 hours.

Sample preparation

3.1.1 Cell culture
Bladder cell lines T24 (high grade UC) and RT112 (low grade
UC) were obtained from Cell Lines Service (CLS GmBH,
Germany) and were cultured in 1:1 mixture of DMEM and
Hams-F12 medium supplemented with 5% fetal bovine serum
and 2 mM L-Glutamine. Flasks were maintained in a humidified atmostphere with 5% CO2 at 37o C. When both cell lines
reached between 80–100% confluency, the culture medium
was removed, and the cells were rinsed with sterile PBS.
Trypsin-EDTA (0.5%) was added to the flask, which was incubated at 37o C until the cells had completely detached (not

3.1.3 Experiment 2: Substrates
Formalin fixed cells were prepared as per Section 3.1.2, and
30 µl of the solution was dropped onto both glass and Ramangrade calcium fluoride (Crystran, UK) substrates respectively,
and left to air dry at room temperature for 2-3 hours.
3.1.4 Experiment 3: Urine exposure times
In order to prepare urine samples containing UC cells, the
cell pellet was suspended in 10 ml artificial urine (AU-001,
Biopanda Diagnostics, UK) and 5 ml PreservCyt. These samples were stored in the fridge for 5 h, 24 h, and 72 h respectively in order to determine the effect of urine exposure
1–12 | 5

on UC cells over an extended time period, and the resulting impact on classification across the two cell lines. Samples were then centrifuged (1200 rpm, 5 min) and decanted,
and the cell pellet was resuspended in 20 ml PreservCyt and
left at room temperature for 15 min. The resulting solution
was centrifuged (1200 rpm, 5 min) and decanted, and the cell
pellet was resuspended in 1 ml PBS. A final centrifugation
step (1200 rpm, 5 min) was carried out, followed by decantation and resuspension in 50 µl PBS. This entire volume was
then dropped onto a glass substrate and left to air dry at room
temperature for 2-3 hours.

3.1.5 Experiment 4: ThinPrep UroCyte
In order to prepare urine samples containing UC cells with
the ThinPrep UroCyte method, the cell pellet was suspended
in 10 ml artificial urine (AU-001, Biopanda Diagnostics, UK)
and 5 ml PreservCyt and stored in a fridge for 24 h. Samples
were then centrifuged (1200 rpm, 5 min) and the supernatant
decanted. In order to compare the differences between cells
exposed only to PreservCyt, and those exposed to both PreservCyt and CytoLyt, the samples were prepared as follows:
(A) A volume of two or three drops of the cell pellet was
suspended in a 20 ml PreservCyt vial and left at room temperature for 15 min. The vial was inserted into the T2 and the
cells were transfered onto a ThinPrep glass slide.
(B) The cell pellet was vortexed and resuspended in 30 ml
CytoLyt. The solution was centrifuged (1200 rpm, 5 min) and
decanted, and two or three drops of the cell pellet were resuspended in a 20 ml PreservCyt vial and left at room temperature for 15 min. The vial was inserted in the T2 system and
the cells were transfered onto a ThinPrep glass slide.

3.1.6 Experiment 5: Hematuria
In order to compare the impact of scant hematuria and frank
hematuria present in urine samples, UC cells were suspended
in 10 ml artificial urine, 5 ml PreservCyt and either 0.5 ml
whole blood (creating a pink solution to represent scant hematuria) or 3 ml whole blood (producing a deep red solution representing frank hematuria). All samples were centrifuged (1200 rpm, 5 min) and decanted. The cell pellet was
vortexed and resuspended in 30 ml CytoLyt. The resulting
solution was centrifuged (1200 rpm, 5 min), decanted, and
a volume of two or three drops of the cell pellet was resuspended in a 20 ml PreservCyt vial and left at room temperature for 15 min. The vial was inserted in the T2 system, and
the cells were transfered onto a ThinPrep glass slide. All experiments were performed in compliance with our institute’s
Ethics Committee, and blood was obtained from a donor following hospital Ethical approval.
6|
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Fig. 1 Schematic of the conventional Raman spectroscopy set-up
used in this study.
OI, optical isolator; LP, linepass filter; ND, neutral density filter;
L, lens; M, mirror; DB, dichroic beamsplitter; DS, dichroic short
pass filter; MO, microscope objective; HL, halogen lamp; CA,
confocal aperture; LgP, long pass filter; DC, digital camera.

3.2

Raman spectral acquisition

A custom-built Raman micro-spectroscopy system was employed for all measurements in this study, as shown in Figure 1. This system consists of a 150 mW laser with 532 nm
wavelength laser (Laser Quantum, Cheshire, UK; Torus),
spectrograph (Andor Technology, Belfast, UK; Shamrock
500) operating with a 600 lines.mm−1 grating, and a cooled
CCD camera (Andor Technology, Belfast, UK; DU420A-BRDD) operating at -80o C, with spectra recorded using the Andor Solis software system. All measurements were recorded
using a 50x/0.8 Olympus UMPlanFl microscope objective and
a 100 µm confocal aperture. The confocal aperture (CA) is
used to ensure that the light reaching the spectrograph has
originated from a specific three dimensional location within
the biological sample. The various lenses in the system are
chosen such that (i) a laser spot size of ∼3 µm is located at
the object plane of the microscope, (ii) the 100 µm confocal
aperture is imaged to the spectrograph slit with a demagnification factor of 4 such that the confocal aperture is matched
to a single camera pixel (25 µm) and the angle of light entering the slit falls within that allowed by the f number of the
spectrograph ( f = 6.5). The confocal aperture serves to provide a spatial resolution of ∼3 µm and helps to reduce the
background signal emanating from the sample substrate and
from optical elements in the Raman system. The long pass filter (Semrock, US; LP03-532RU-25) and dichroic beamsplitter (Semrock, US; LPD-01-532RS) were chosen to filter out

the laser wavelength from reaching the spectrograph; the latter having the property of reflecting the laser wavelength at an
operating angle of 45 degrees, while transmitting the longer
Raman scattered wavelengths. The 45o dichroic shortpass
filter (Edmund Optics, US; 69-202) reflects all wavelengths
greater than 500 nm while allowing shorter wavelengths from
the halogen lamp to pass through, which permits imaging of
the sample of the digital camera (Basler, Germany; acA2000340km). Spectra were recorded within the 400–1800 cm−1
range with an acquisition time of 5 s each. Two spectra were
recorded from the same location within the nucleus of 50 cells
from each slide.
3.3

Data processing

Raman spectra from biological samples are complex owing to
their heterogeneous nature. These spectra consist of peaks that
correspond to a range of biomolecules such as proteins, lipids,
carbohydrates, and nucleic acids. Subtle changes across these
spectra can provide critical pathological information that can
be used for disease classification. However, these subtle
changes are often masked by large background signals and
signals associated with surrounding materials that are unrelated to the sample of interest. Therefore, data is often preprocessed to help eliminate these unwanted signals, and to further
enhance the spectral features associated with the sample.
The recording of two spectra facilitates the subsequent removal of cosmic rays as described by James et al. 32 Following
this, a baseline/background subtraction algorithm is applied,
based on that developed by Kerr et al. 33 This algorithm computes an optimum baseline made up of an N order polynomial
and a weighted substrate/background signal that is recorded
at the beginning of each experiment (e.g. signal from a glass
slide). The weight of the substrate spectrum, and the selection
of the N order polynomial are determined based on a least
squares algorithm, in which a given spectrum is estimated to
be given by the sum of (i) a weighted ideal gold standard bladder cell spectrum free of background contamination, (ii) the
weighted glass background signal, and (iii) an N order polynomial. Following determination of the “best fit” for a given
spectrum, components (ii) and (iii) are subtracted from the
spectrum. In order to remove any potential bias, the same gold
standard cell spectrum was used for all experiments; this spectrum is the mean of the T24 cell line recorded on CaF2 . In all
cases a 1st order polynomial was used in the baseline subtraction algorithm, except for the case of T24 and RT112 formalin
fixed on glass, which had a particularly strong baseline signal
due to experimental parameters on that given day; in this case
N was chosen to be 7. Additionally, all spectra were smoothed
with a Savitzky-Golay filter (k = 5; w = 7).
In order to compare the spectra recorded across the various parameters discussed in Section 2, and in order to de-

termine the impact of these parameters on the classification
of both cell lines, a combination of PCA and LDA was applied to the two groups in each of the five experiments. The
sensitivity and specificity values were determined based on a
leave-one-out cross validation method, as described in more
detail elsewhere. 34,35 All data processing was applied using
Matlab R (Matlab, MathWorks Inc., USA).
3.4

Haematoxylin & Eosin staining

Following Raman spectral acquisition, all samples prepared
with the ThinPrep UroCyte method were H&E stained. 36 This
was achieved by placing the slides into a bath of 95% alcohol for 10 min, and then washed with water. Slides were
placed into a bath of Harris haematoxylin (Sigma Aldrich,
US) for 5 min, and then transferred into a bath of water before being submerged into a bath of 1% acid-alcohol for 1 s,
washed with water, and placed into a bath of water for 5 min
to ’blue’ the haematoxylin. Slides were placed into a bath of
1% eosin (Sigma Aldrich, US) for 3 min in order to counterstain the cytoplasm, following which the slides were submerged in water for 1 s, 95% alcohol for 1 s, and 100% alcohol
for 1 s. The slides were placed into bath of 100% alcohol for
5 min, and were then transferred into a bath of xylene (Sigma
Aldrich, US) for 3 min, and a second bath of xylene for a further 3 min. Finally, the slides were removed and a coverslip
applied with DPX mounting medium (Thermo Fisher Scientific, Ireland) and were left to dry. Following staining, cells
were examined under a photomicroscope, with a 40x microscope objective, for changes relating to different stages of cancer such as abnormal cellular shape and size, abnormal nuclei,
and cellular arrangement/distribution. The amount of residual
blood cells present on the slide from hematuria contaminated
samples was also monitored. Alternatively, slides could have
been Pap stained if this method was prefered.

4
4.1

Results
Experiment 1: Fixing agents

The spectra shown in Figure 2 represent the mean Raman
spectra recorded from T24 UC cells for the cases of unfixed/fresh, formalin fixed, and PreservCyt fixed respectively.
All of these spectra were recorded on glass substrates, and the
data processed as described in Section 2.3. Formalin fixed
cells were found to be most similar to unfixed cells with no
significant spectral differences observed. PreservCyt fixed
cells were found to have differences in the intensity of some
peaks within the fingerprint region; an increase can be seen in
the peaks at 1093 cm−1 and 1250 cm−1 , which relate to PO2
stretching (DNA/RNA), and a decrease in peaks at 750 cm−1 ,
1310 cm−1 , 1340 cm−1 , and 1580 cm−1 , corresponding to
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Fig. 2 Mean spectrum fresh/unfixed T24 cells (black), formalin
fixed T24 cells (red) and PreservCyt fixed T24 cells (green). All
cells were drop-dry deposited onto glass slides.

Fig. 3 Mean spectrum of T24 and RT112 formalin fixed UC cells
recorded on calcium fluoride and glass substrates; all spectra were
preprocessed as described in Section 2.2.

tryptophan, collagen twisting modes, guanine, adenine, and
bending modes of phenylalanine. 37
For each fixation method, a PC-LDA training model was
implemented based on a leave-one-out cross validation in
order to classify T24 and RT112 UC cells. The resulting sensitivities and specificities were 100% and 98.0% for
fresh/unfixed T24, 98.0% and 100% for formalin fixed cells,
and 100% and 100% for PreservCyt fixed cells respectively.
These classification values indicate that the three fixing agents
measured here have no significant impact on the ability of PCLDA to classify spectra across both cell types. This demonstrates that PreservCyt fixation of cells, a common preservation method used across clinics today, can be integrated into
Raman micro-spectroscopy.

Fig. 4 Mean spectrum of T24 and RT112 UC cells after exposure to
urine and PreservCyt for 5 h, 24 h and 72 h; all spectra were
recorded on glass substrates.

4.2

4.3

Experiment 2: Substrates

The spectra shown in Figure 3 represent the mean preprocessed Raman signals recorded from T24 and RT112 cells
recorded on Raman-grade calcium fluoride and glass substrates. Prior to background subtraction, there was a significant glass contribution present within the 1020–1120 cm−1
region. 26 However, following background subtraction it can
be seen that there are minimal differences between spectra
recorded on calcium fluoride and glass subtrates. Classification values between both cell lines remained consistent across
both substrates, resulting in sensitivities and specificities of
greater than 98%, which indicates that glass can be used as
a substrate within a clinical study without compromising on
diagnostic accuracies.
The results from Experiment 2 have shown that standard
glass slides can be used with Raman micro-spectroscopy to
produce diagnostic results that are similar to those obtained
from expensive calcium fluoride substrates, provided a 532 nm
laser and a robust background subtraction algorithm are employed.
8|
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Experiment 3: Urine exposure times

In order to test the ability of Raman based classification to differentiate between cells that have been exposed to urine, both
cell lines (T24 and RT112) were exposed to artificial urine and
PreservCyt for 5 h, 24 h and 72 h, followed by an additional
PreservCyt fixing step as described in more detail in Section
2.1.4. All samples were then washed with PBS, which is not
included in the ThinPrep method. This additional washing
step was carried out to remove spectral contamination from the
residual PreservCyt solution from interfering with the Raman
spectra recorded from the cells. It should be noted that this
may cause a reversal of the fixation process. This additional
washing step was not required with the ThinPrep method, used
in experiments 4 and 5, due to its filter-based properties.
The associated mean (pre-processed) spectra for these three
time periods are shown in Figure 4. For each exposure time,
a PC-LDA training model was implemented based on a leaveone-out cross validation, and the corresponding sensitivities
and specificities are listed in Table 1, where it can be seen that
it is still possible to accurately differentiate between both cell

Fig. 5 Mean spectra of T24 and RT112 UC cells after exposure to
urine and PreservCyt for 24 h, followed by ThinPrep processing
with and without the addition of the red blood cell lysing agent
CytoLyt.

lines after 72 h. Interestingly, when the data from all three
time durations is combined, the classification accuracies remain above 90%, which indicates that PreservCyt can preserve
cells in urine for up to 3 days without significantly altering the
cell biochemistry or the diagnostic potential of the method.
4.4

Fig. 6 Images obtained from H&E stained UC cells after Raman
spectral analysis, prepared with the ThinPrep UroCyte method. (A)
RT112 cells and (B) T24 cells without CytoLyt; (C) RT112 and (D)
T24 cells with CytoLyt.

spectral acquisition, thus allowing for both Raman and standard urine cytology to be performed on the same slide.

Experiment 4: ThinPrep UroCyte

Figure 5 shows the mean preprocessed spectra recorded from
T24 and RT112 UC cells after exposure to urine and PreservCyt for 24 h, with and without the addition of the red blood cell
lysing agent CytoLyt, followed by ThinPrep processing. Here,
it can be seen that CytoLyt has no significant impact on UC
cells, and no spectral contributions were observed from cells
that were exposed to CytoLyt compared with those exposed to
PreservCyt alone. The spectra recorded from ThinPrep processed slides were more consistent than those measured with
the drop-dry method, i.e. a smaller standard deviation was
measured across the spectra from both T24 and RT112. It is
possible that this is due to the uniform monolayer deposition
method employed by the T2 machine compared to the random
distribution of cells that can accumulate on the slide after the
drop-dry method.
A PC-LDA model was generated based on a leave-one-out
cross validation method for both of these methods individually
and combined, and the results are displayed in Table 1. The
sensitivities and specificities found are greater than 88%.
Figure 6 shows the images obtained from these slides after H&E staining (after Raman spectral acquisition); distinct
differences can be seen between both cell lines in terms of cellular shape and size, along with more abnormal nuclei present
in T24 UC cells, as expected. The cells do not appear to have
been photodamaged by the laser, which indicates that a pathologist should still be able to perform standard urine cytology
diagnostics on slides that have been stained following Raman

4.5

Experiment 5: Hematuria

Spectra recorded from cells obtained from ThinPrep processed
urine samples replicating scant and frank hematuria are shown
in Figure 7. Here, it can be seen that cells obtained from a
urine sample with scant hematuria appear to be free from any
contamination; this is due to the effective removal of many of
the red blood cells present in the sample by the lysing agent
CytoLyt. However, for the frank hematuria sample, several additional peaks have been observed that correspond to the presence of residual blood cells, a further breakdown of the peaks
associated with blood cells can be found elsewhere. 38 This
result indicates that samples that have relatively high blood
cell concentrations are not suitable for diagnostics with Raman micro-spectroscopy, although further investigation into
additional CytoLyt washes or the use of H2 O2 as suggested by
Bonnier et al. 17 could possibly help to remove residual blood
from these samples.
Figure 8 shows the H&E stained images obtained from both
samples containing scant and frank hematuria respectively.
Here small regions of blood remain visible within the scant
hematuria sample, but the majority of UC cells in this sample
appear to be isolated from the blood regions. The frank hematuria sample, however, has a low UC cell yield, and contains
large regions of blood contamination. It is possible that this is
due to large amounts of blood cells gathering on the ThinPrep
filter, resulting in less space for the UC cells. This demonstrates the importance of removing blood cells with a lysing
1–12 | 9

Table 1 Sensitivity and specificity values for T24 and RT112 cell
lines after urine exposure based on a PC-LDA model with
leave-one-out cross validation, for the drop-dry and ThinPrep
deposition methods
Sens.

Spec.

Drop-dry method:
T24 - 5 h urine exposure
RT112 - 5 h urine exposure

97.9%
94.2%

94.2%
97.9%

T24 - 24 h urine exposure
RT112 - 24 h urine exposure

97.9%
96.1%

96.1%
97.9%

T24 - 72 h urine exposure
RT112 - 72 h urine exposure

100%
100%

100%
100%

T24 - Combined urine exposure times
RT112 - Combined urine exposure times

91.5%
93.2%

93.2%
91.5%

ThinPrep method:
T24 - 24 h urine - PreservCyt only
RT112 - 24 h urine - PreservCyt only

94.3%
100%

100%
94.3%

T24 - 24 h urine - PreservCyt and CytoLyt
RT112 - 24 h urine - PreservCyt and CytoLyt

96.0%
96.0%

96.0%
96.0%

T24 - Both ThinPrep samples
RT112 - Both ThinPrep samples

88.4%
99.0%

99.0%
88.4%

agent as well as applying additional washes to further remove
this contamination.

5

Conclusion

In this paper the ability of Raman micro-spectroscopy to discriminate between low and high grade bladder cancer cell lines
with a high degree of accuracy has been demonstrated, even
within the practical constraints of a typical pathology laboratory. Five separate experiments were conducted that validate
the performance of Raman based classification when applied
as an adjunct to the standard practice of urine cytology.
In the first experiment, it was concluded that the Raman
spectra obtained from cells following fixation, using the commercial methanol based fixative, PreservCyt, are not significantly different to those recorded from fresh/unfixed cells and
formalin fixed cells, with negligible differences in statistical
classification accuracies observed. This is an important result;
not only does it demonstrate that Raman micro-spectroscopy
can easily be adopted into the standard urine cytology protocol within a clinical setting, but it also provides an alternative to the use of formalin, a common fixative of choice in
Raman based cell studies, 27,29,39 which is a known carcinogen. 40 While it has been shown by Harvey et al. 22 that the al10 |
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Fig. 7 Mean spectrum of T24 and RT112 UC cells after exposure to
urine and PreservCyt for 24 h with the addition of blood to replicate
scant and frank hematuria. All samples were ThinPrep processed
with the red blood cell lysing agent CytoLyt.

Fig. 8 H&E stained images of (A) RT112 cells from a scant
hematuria urine sample, and (B) T24 cells from a frank hematuria
urine sample. Both samples were processed with CytoLyt and the
ThinPrep method.

cohol based fixative SurePath could be used as part of the BD
SurePath liquid-based Pap test, SurePath was shown to produce a large signal within the fingerprint region, which makes
PreservCyt a preferable fixative for urine cytology samples.
In the second experiment, it was concluded that the spectra
recorded from cells on glass were comparable to that recorded
on calcium fluoride substrates. It has recently been published
by our research team that comparable Raman spectra can be
obtained from biological cells across different substrates with
the proviso that a robust background subtraction algorithm is
employed. 26,33 Here we have shown that a low and high grade
bladder cancer cell line (both formalin fixed) can be accurately
classified using PC-LDA when recorded on both calcium fluoride and glass substrates. This result indicates that glass slides
can be used in clinical Raman studies when combined with
a 532 nm laser, which is significantly less expensive than the
use of calcium fluoride substrates.
In the third experiment, it was shown that UC cells can be
exposed to urine for up to 3 days in the presence of PreservCyt
without significantly altering the cellular biochemistry. The
ability to accurately classify between two cell lines after exposure to urine for 5 h, 24 h and 72 h has not been significantly

affected (see Table 1). Interestingly, the results in Table 1 indicate that the sensitivities and specificities increase slightly
with longer urine exposure times, however, is more likely to
be related to minute changes in the system’s alignment or sample preparation methods rather than an improved accuracy that
corresponds directly to urine exposure times. Therefore, the
combined sensitivities and specificities (91.5% and 93.2% respectively) are a better representation of this method. This result indicates that it may be possible to transport urine samples
from a clinic into a Raman lab within a realistic time frame.
It is impractical to consider analysing urine samples that have
not been exposed to a preservative unless the samples will be
processed within a few hours of urine collection due to the
rapid deterioration of cells in urine. 41
Additionally, in a clinical setting, the urine collection
method is important to avoid unwanted contaminants from entering into the sample such as bacteria, fungal infections, and
other genital contamination. Therefore, it is typically recommended that patients follow the “clean catch”, “mid-stream”
method. The ThinPrep UroCyte method advises for this urine
to be stored in a 2:1 ratio with PreservCyt to avoid further cell
degradation.
In the fourth experiment, it was demonstrated that the ThinPrep UroCyte method can be applied in combination with
Raman micro-spectroscopy resulting in spectra that have a
smaller standard deviation than that obtained from cells deposited onto a slide via the drop-dry method. This is most
likely due to the uniform monolayer deposition method employed by ThinPrep, as seen in Figure 5. ThinPrep also
provides a cleaner background, increased cellularity, better
preservation, and facilitates easier and faster preparation. 30
The two chemicals employed by the ThinPrep UroCyte
method have little impact on the Raman spectra obtained, and
no significant impact in diagnostic classification results were
observed. Uniform cellular distribution resulted in smaller deviations in the background signal when compared to the spectra obtained from cells deposited onto a slide via the drop-dry
method. Cells did not require any washing steps after fixation
in PreservCyt with ThinPrep due to its filter based properties,
whereas drop-dried cells needed further washing with PBS in
order to avoid spectral contamination from the PreservCyt solution. Additional washing steps could result in a reversal of
the fixation process of PreservCyt.
The sensitivity and specificity values calculated for ThinPrep prepared samples, as shown in Table 1, are greater than
88%. Whilst these results are slightly lower than those found
for the drop-dry method, ThinPrep offers many other advantages that make it a preferrable deposition method for Raman
micro-spectroscopy. These advantages include ease of preparation, which is particularly important in a busy clinic, the inclusion of red blood cell lysing agents, and a monolayer distribution of cells across the slide where one focal depth is suf-

ficient to analyse most of the cells on the slide.
In the fifth experiment, the impact of hematuria on the spectra recorded from UC cells obtained from a urine sample was
investigated. Approximately 90% of patients diagnosed with
bladder cancer will present with hematuria. Therefore, it is
inevitable that Raman spectra will have to be recorded from
patients with blood in their urine. The amount of blood will
vary from patient to patient, resulting in urine of a mild pink
colour (scant hematuria) to deep red (frank hematuria), with
the most severe cases resembling the colour of coffee. In this
experiment it was shown that urothelial cells can be easily
separated from blood in scant hematuria samples using ThinPrep and CytoLyt, as can be seen in Figure 8(A). However,
it is more difficult to fully remove red blood cells from frank
hematuria samples, resulting in urothehelial cells being deposited on to the slide in very close proximity to regions of
blood residue (Figure 8(B)). The consequence of this is that
the Raman spectra obtained from UC cells are contaminated
by spectral peaks associated with blood. Additional CytoLyt
washes should help to further eliminate this problem, but it
may be necessary to wait for the patient to provide a sample
at a later date when their levels of hematuria have lowered,
e.g. after an antibiotic for infection, or medication for kidney
stones, etc.
There are additional factors associated with urine cytology
samples which have not been considered here, such as the ability to identify UC cells that are randomly distributed across a
slide containing healthy urothelial cells, squamous and glandular cells, renal tubular cells and casts, inflammation, infection or blood components. It must be noted that in this paper and in previous literature on Raman based urine cytology,
the number of cells to be recorded from each slide has not
been considered in great detail. Shapiro et al. reported recording only five cells per slide; however, since it is possible for
the majority of urothelial cells in a typical sample to be noncancerous, it is unknown how these five cells were chosen or
identified. 24 An important problem with standard urine cytology is the inability to differentiate between healthy cells and
low grade cancer cells under a microscope, and this task becomes more difficult when the cells are unstained, as required
by Raman micro-spectroscopy. Therefore, one reasonable approach may be to record spectra from every available urothelial cell on the slide, and to monitor if any of these cells are
classified as cancerous by the trained statistical algorithm. If a
cell is identified as such, the corresponding patient could then
be flagged for further investigation. Alternatively, it may be
possible to train image processing algorithms to identify cells
of interest.
Similarly, the number of patients that should be used to
accurately train a classifier needs to be further examined.
Beleties et al. reported that a sample size of 75–100 is typically needed to achieve a good, but not perfect, classifier. 42
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However, it is difficult to train a classifier from urine cytology
samples due the low sensitivities associated with the standard
urine cytology method; thus, training of algorithms based on
biopsy and tissue samples with a known pathological status
may be preferable.
In summary, the combination of Raman micro-spectroscopy
and the ThinPrep UroCyte method provides an ideal platform
to replace cystoscopy for bladder cancer surveillance, particularly for high-risk patients who otherwise would require frequent repeat cystoscopic procedures. Raman based urine cytology provides all of the advantages associated with standard
urine cytology, i.e. ease of procurement, non-invasive and low
cost, as well as the advantages of high sensitivity and specificity typically associated with cystoscopy. This technique
would help to significantly lower the financial burden associated with bladder cancer surveillance for health care systems
worldwide, as well as improving the patient’s quality of life.
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